베타
임상 레이더 AI
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰

Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring

철회
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT00796848은(는) 당뇨병에 대해 알아보는 중재연구입니다. 현재 상태는 철회이며, 연구는 2009년 3월 1일에 시작되어 해당 없음명의 참여자를 모집하고 있습니다. 스탠퍼드 대학교이(가) 진행하며, 2010년 3월 1일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2018년 6월 6일에 갱신되었습니다.
간단한 개요
The purpose of doing this study is to see if continuous glucose monitoring can help people with type 1 diabetes who are sometimes unable to feel if they have a low blood glucose reading. For this study we will be using the Navigator Continuous Glucose Monitor. We think that your body may not have enough of a certain hormone that usually helps people know when they are going low. If you can keep from going low, we thi...더 보기
상세한 설명
To enroll in this study you must be between the ages of 7 and 20, have type 1 diabetes, and experience at least two episodes of low blood glucose readings weekly that you do not feel. Up to 25 subjects will be enrolled at Stanford and another 25 at the Barbara Davis Center in Colorado. The study will last approximately 8 months for each participant.
공식 제목

Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring

질환명
당뇨병
기타 연구 식별자
  • SU-10172008-1323
  • Stanford eprotocol #14728 (기타 식별자) (Stanford IRB)
NCT 번호
실제 연구 시작일
2009-03
최신 업데이트 게시
2018-06-06
예상 연구 완료일
2010-03
연구종류
중재연구
단계/상
해당 없음
상태
철회
주요 목적
치료
설계 할당
무작위배정
중재 모델
교차 설계
맹검 (마스킹)
없음 (오픈 라벨)
시험군 / 개입
참가자 그룹/시험군개입/치료
해당 없음
Navigator Continuous Glucose Monitor
주요결과변수
결과변수측정값 설명시간 범위
To evaluate the effectiveness of continuous glucose monitoring in the reduction of hypoglycemia unawareness.
이차결과변수
결과변수측정값 설명시간 범위
To assess the levels of epinephrine production in youth diagnosed with hypoglycemia unawareness with and without continuous glucose monitor wear.
적격성 기준

연령대
어린이, 성인
최소 연령
7 Years
참여 가능한 성별
전체
  1. Be at least 7 to 20 years old
  2. Have been diagnosed with type 1 diabetes for at least 1 year
  3. Report 2 or more episodes per week of asymptomatic hypoglycemia as determined by completion of the Hypoglycemia Awareness Questionnaire (HAQ) or as determined by Investigator
  4. HbA1c level < 10%
  5. Internet access for downloading continuous glucose monitoring (CGM), access to a compatible computer (Windows Vista is not compatible for downloading.)
  6. For females, you are not intending to become pregnant during the study
  7. No expectation that you will be moving out of the area for the duration of the study

  1. The presence of a significant medical disorder (including epilepsy, or any cause of seizures other than hypoglycemia) that in the judgment of the Investigator will affect the wearing of the sensors or the completion of any aspect of the protocol
  2. Treatment with systemic or inhaled corticosteroids in the last six months
  3. Inpatient psychiatric treatment in the past six months for you or your primary caregiver
  4. Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the Investigator would be a contraindication to participation in the study
  5. Having two or more severe hypoglycemia episodes (seizure or loss of consciousness) in the six months prior to enrollment
  6. Having a severe hypoglycemic episode in the 30 days prior to enrollment
연구 책임자
Bruce A. Buckingham, 책임연구자, Principle Investigator, Stanford University
연락처 정보가 없습니다.
1 1개국에 임상시험 장소

California

Stanford University School of Medicine, Stanford, California, 94305, United States